SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-025274
Filing Date
2020-05-14
Accepted
2020-05-14 07:44:41
Documents
65
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q prvl-10q_20200331.htm 10-Q 1932594
2 EX-31.1 prvl-ex311_6.htm EX-31.1 18633
3 EX-31.2 prvl-ex312_8.htm EX-31.2 18608
4 EX-32.1 prvl-ex321_7.htm EX-32.1 17887
  Complete submission text file 0001564590-20-025274.txt   6232873

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT prvl-20200331.xml EX-101.INS 1146981
6 XBRL TAXONOMY EXTENSION SCHEMA prvl-20200331.xsd EX-101.SCH 47972
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE prvl-20200331_cal.xml EX-101.CAL 34441
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE prvl-20200331_def.xml EX-101.DEF 197922
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE prvl-20200331_lab.xml EX-101.LAB 376299
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE prvl-20200331_pre.xml EX-101.PRE 316877
Mailing Address 430 EAST 29TH STREET, SUITE 940 NEW YORK NY 10016
Business Address 430 EAST 29TH STREET, SUITE 940 NEW YORK NY 10016 917-336-9310
Prevail Therapeutics Inc. (Filer) CIK: 0001714798 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38939 | Film No.: 20875307
SIC: 2836 Biological Products, (No Diagnostic Substances)